6621.Two
6621.TWO operates in the healthcare equipment industry, specializing in the development and provision of advanced medical equipment and technology.
Business. 6621.TWO operates in the healthcare equipment industry, specializing in the development and provision of advanced medical equipment and technology.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6621.TWO operates in the healthcare equipment industry, specializing in the development and provision of advanced medical equipment and technology.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 4.86, supported by cash and equivalents of 28,997,000 TWD. However, the company reported negative operating and free cash flows of -36,674,000 TWD and -35,424,000 TWD, respectively, suggesting operational cash generation challenges.
Profitability metrics are underperforming, with a return on equity of -17.64% and a return on assets of -14.74%. These figures are significantly below the industry norms for advanced medical equipment and technology firms, indicating a need for operational improvements or strategic shifts to enhance returns.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in a volatile industry like healthcare equipment.
The company's growth trajectory is currently negative, with a reported net loss of 40,544,000 TWD and an operating loss of 44,125,000 TWD. There are no disclosed plans or outlooks for the next fiscal year that suggest a reversal of this trend, and the absence of positive revenue growth in the recent period indicates a challenging market environment.
Risk factors include the company's negative operating and free cash flows, which could impact its ability to fund operations and invest in growth. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative cash flows and operating losses may necessitate future financing, which could lead to dilution if not managed carefully.
Recent events, as disclosed in the latest financial filings, include a significant operating loss and a net loss, with no material events or strategic initiatives reported that would suggest a turnaround in the near term. The company's capital expenditures were minimal at -1,879,000 TWD, indicating a lack of investment in growth or expansion.
- The company is operating at a loss, with negative operating and net income, indicating poor profitability.
- The company has a strong liquidity position with a high current ratio, but is generating negative cash flows from operations.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
- The company lacks geographic and segment diversification, increasing its exposure to market-specific risks.
- The company's growth trajectory is negative, with no clear signs of improvement in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6621.TWO Market data — financials · 2026-05-27